Devens, MA -- (SBWIRE) -- 06/01/2022 -- For over four decades, YMC has striven to provide solutions to biopharmaceutical and pharmaceutical companies that utilize purification processes in the development of drug therapies. The need for a cost-effective approach to purification is essential to increase yields and reach target purity levels.

YMC is once again leading the industry with the Multicolumn Countercurrent Solvent Gradient Purification process or MCSGP. This process is being widely adopted by large-scale enterprises to accelerate production, increase yields, and reduce overall costs in the purification process. Some of the benefits of MCSGP include:

An appreciable decrease in synthesis batches needed (increasing capacity)

An overall reduction in Quality Control analysis and handling processes

Potential reductions in solvent consumption leading to decreased costs during production

YMC will be discussing the MCSGP approach to purification at the upcoming World Biopharma Forum 2022. Representatives from the company will cover the current data available regarding the implementation of this process, as well as the many benefits that have been reported from the companies already utilizing it. In addition, YMC staff will also discuss upcoming iterations of MCSGP that will enable end-users to further increase both yields and purities in peptide and oligonucleotide-based therapies.

For more information about this upcoming event, please visit .

YMC is a pioneer in developing technology that handles the complexities of separation and purification. Their team continues to improve the product line to provide the biopharmaceutical and pharmaceutical industries with cutting-edge technologies to reduce costs, increase efficiency, and boost productivity. Silica-based products like YMC-Pack Pro C18 and other glass accessories will provide effective solutions for countless applications decreasing production time and improving results.

If you are interested in learning more about YMC, you can contact them online or call 1-(888)-341-8380.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Devens, MA -- (SBWIRE) -- 06/30/2021 -- YMC America has recently completed the successful co-location and expansion of its US business operations at its growing campus in Devens, Massachusetts.

The purpose of the move was to consolidate operations in a single facilities center while adding a much-needed expansion of resources, space, and laboratories. The Devens, MA, location puts YMC America's facilities at the doorstep of the epicenter of the global bio/pharma industry.

Formerly located in Allentown, PA, was YMC America's operations hub and laboratory for stationary phases and columns. The facilities in Devens have always served as home to R&D, design, and manufacturing for YMC America's lab and GMP-scale purification systems for large and small molecules.

The combination of operations unifies teams of like interests. It also positions the company for additional long-term growth.

Already underway is a new lab facility in a recently acquired building adjacent to the current site in Devens. This lab facility will support all YMC America products and serve as a center for conducting short and long-term studies as well as host hands-on customer training.

The company also recently opened a lab in Thousand Oaks, CA.

YMC America provides a range of chromatography materials, columns, instruments, purification systems, and services that enable small and large molecule researchers and manufacturers to facilitate the cost-effective production and QC of next-generation pharmaceutical therapies. This expansion of capabilities will bring closer together the lab/GMP systems manufactured by YMC's bio/pharma systems group and the consumable components of YMC (resins, pre-packed columns, related accessories), leading to a positive impact for YMC customers.

Beyond consolidation, the addition of a new lab building will enable YMC and YMC customers to evaluate and develop processes using the entire suite of YMC purification products. For example, the leading C18 chemistries (YMC-Triart) have recently proven to further enhance the productivity of novel YMC system technologies, including YMC's patented MCSGP technology for continuous purification of peptides, oligos, RNA- and DNA-based therapies, and vaccines.

This strengthening of capabilities in the Americas helps to build on YMC's global leadership in continuous separation/purification technology. In Kyoto, Japan, at its recently opened lab complex known as "Kyoto Works," YMC is escalating R&D of the continuous separation/purification platform in parallel with the expansion at the Devens location.

The YMC Group plans to accelerate the development of the continuous separation/purification business on a global basis by leveraging its manufacturing, R&D, and laboratory infrastructures in Japan, Europe, and the Americas.

To learn more or buy HPLC columns, visit https://www.ymcamerica.com/ today.

About YMC Co., Ltd.
YMC is a private life science company headquartered in Kyoto, Japan. Founded in 1980, YMC has 9 affiliates and facilities in Asia, Europe, and the Americas. Over 500 YMC employees are providing best-in-class lab and process solutions to bio/pharmaceutical industry.

YMC delivers and supports these solutions in all major global geographies on six continents.

YMC's focus is on innovation, production, and sales of packing materials, packed columns, and systems for High Performance Liquid Chromatography (HPLC), Low Pressure Liquid Chromatography (LPLC) and custom purification and custom synthesis.

YMC operates a CMO facility and pilot plant incorporating state of the art simulated moving bed (SMB) purification.

YMC America has been in operation for over 30 years serving the Americas. In 2019, YMC acquired the former LEWA Process Technologies (Devens, MA USA) and ChromaCon AG (Zurich, CH).

YMC's intellectual properties, cultivated from many years of experience, will continue to push the limits to create a prosperous future for purification and discovery of small and large molecule therapies.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Devens, MA -- (SBWIRE) -- 05/07/2021 -- YMC-Triart is a widely-utilized family of stationary phases for HPLC and Prep LC. YMC has recently developed a YMC-Triart phase ideal for peptides with aromatic residues.

With the addition of YMC-Triart Prep Phenyl-S to the Company's family of hybrid particle-based stationary phases designed for preparative separations, YMC now offers a series of prep-specific phases with overlapping selectivity. This enables the developer of the separation to choose the YMC-Triart Prep phase based on the best separation of the most critical peak pair. This is the basis for a productive purification process with high loadability.

Under the name YMC-Triart Prep Phenyl-S, this new stationary phase is an extension of the YMC-Triart product line that has inherited the fundamental advantages of the YMC-Triart hybrid base particle.

All YMC-Triart phases start with the same type of novel inorganic/organic hybrid silica. This hybrid particle technology offers two crucial advantages to users involved in small or large production scale peptide purification.

YMC-Triart Prep Phenyl-S is mechanically stable and physically strong. This means that the media can be repeatedly packed, unpacked, and repacked, with minimal particle fracturing. Particle fractures (fines) are commonplace with conventional silica-based media and lead to increased backpressure. YMC-Triart media overcomes the weakness that is the principal cause of particle fracturing.

The physical strength of YMC-Triart media also enables greater success when using dynamic compression columns (typically, dynamic axial compression [DAC] columns). Dynamic compression exerts pressure onto the packed bed to keep it uniform and organized, but the compression can lead to the crushing of conventional particles.

Another essential advantage of YMC-Triart Prep Phenyl-S is the stability of chemicals. The media is consistent at any pH from 1 to 10 (in regular use) and up to pH 12 for clean-in-place. This consistency enables the use of alkaline (or acidic) cleaning in place (CIP) protocols at extreme pH that are too harsh for conventional media. The use of CIP protocols is important in peptide purification to reverse the deterioration of media performance caused by the adsorption of proteins.

Contact YMC America at info@ymcamerica.com or call 888-341-8380 to learn more or buy columns today.

About YMC
YMC is a private life science company headquartered in Kyoto, Japan. Founded in 1980, YMC has 9 affiliates and facilities in Asia, Europe, and the Americas. Over 500 YMC employees are providing best-in-class lab and process solutions to bio/pharmaceutical industry.

YMC delivers and supports these solutions in all major global geographies on six continents.

YMC's focus is on innovation, production, and sales of packing materials, packed columns, and systems for High Performance Liquid Chromatography (HPLC), Low Pressure Liquid Chromatography (LPLC) and custom purification and custom synthesis.

YMC operates a CMO facility and pilot plant incorporating state of the art simulated moving bed (SMB) purification.

YMC America has been in operation over 30 years serving the Americas. In 2019, YMC acquired the former LEWA Process Technologies (Devens, MA USA) and ChromaCon AG (Zurich, CH).

YMC's intellectual properties, cultivated from many years of experience, will continue to push the limits to create a prosperous future for purification and discovery of small and large molecule therapies.

See: https://www.ymcamerica.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Devens, MA -- (SBWIRE) -- 04/12/2021 -- Insulin is a peptide hormone. Due to the typical scale of insulin production and market pressures to increase availability and reduce the cost of insulin, there is justification to invest resources into finding improved conditions and materials for insulin purification.

YMC participated in a detailed cost calculation analysis for insulation purification under the supervision and with the cooperation of a leading insulin manufacturer.

The results of the study have been released by YMC in a case study entitled How to reduce the costs for preparative LC processes.

The case study points out that there are three cost drivers associated with preparative LC processes: labor/overhead comprises roughly 56 percent of the cost; mobile phase consumption accounts for 31 percent; and the stationary phase accounts for the remaining 13 percent — the smallest portion of the cost.

Ironically, it is the stationary phase that can exert the most significant impact on the processing time (overhead) and mobile phase consumption — the lowest contributor to cost has the greatest impact on overall cost-effectiveness.

In the case study, several stationary phases were tested (all of them C8 reversed-phase). Based on the tests, the study performed a careful cost estimation for the isolation of 100kg of purified insulin.

Key factors in the cost projections included insulin recovery, the amount of crude insulin required to produce 100g of 99.5% pure product, the required number of purification cycles, fraction volume per run, the number of days required to reach the goal of 100g, and the total volume of solvent required.

In the study, YMC-Triart Prep Bio200 C8 outperformed all other phases in the test, not just in overall projection but in each individual metric.

YMC-Triart Prep Bio200 C8 accounted for the achievement of the goal of 100g of 99.5% pure insulin in the shortest period of time, with the lowest number of injections, the lowest amount of solvent required, and the smallest amount of crude insulin required. Overall, the projected savings in purification costs are up to 40 percent.

Not included in the projection is the fact that YMC-Triart Prep Bio200 C8 is known to have over 2x the lifetime of the other materials used in the study. This means that not only does YMC-Triart provide more efficient results, but it can be expected to show that efficiency even when used twice as long as other materials.

YMC-Triart Prep Bio200 C8 is a reversed-phase material built on a unique organic-inorganic silica hybrid particle. The physical strength of the particle, combined with the chemical stability of the synthesized stationary phase, accounts for the long life of the material. In addition, YMC-Triart Prep Bio200 C8 is produced with a 200 Angstrom pore size — which proves to be an ideal middle-range pore size that is optimized for the molecular size of peptides.

Click here to read the case study found on the YMC America website.

For more information, contact a YMC America representative by emailing info@ymcamerica.com or calling 888-341-8380. Buy columns and guards online at https://www.ymcamerica.com/.

About YMC
YMC is a private life science company headquartered in Kyoto, Japan. Founded in 1980, YMC has 9 affiliates and facilities in Asia, Europe, and the Americas. Over 500 YMC employees are providing best-in-class lab and process solutions to bio/pharmaceutical industry.

YMC delivers and supports these solutions in all major global geographies on six continents.

YMC's focus is on innovation, production, and sales of packing materials, packed columns, and systems for High Performance Liquid Chromatography (HPLC), Low Pressure Liquid Chromatography (LPLC) and custom purification and custom synthesis.

YMC operates a CMO facility and pilot plant incorporating state of the art simulated moving bed (SMB) purification.

YMC America has been in operation over 30 years serving the Americas. In 2019, YMC acquired the former LEWA Process Technologies (Devens, MA USA) and ChromaCon AG (Zurich, CH).

YMC's intellectual properties, cultivated from many years of experience, will continue to push the limits to create a prosperous future for purification and discovery of small and large molecule therapies.

See: https://www.ymcamerica.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Devens, MA -- (SBWIRE) -- 04/05/2021 -- Hydrophobic interaction chromatography (HIC) is often useful for antibody separations because running conditions are non-denaturing, and differences in protein surface-associated hydrophobicity offer high selectivity.

YMC BioPro HIC BF is a HIC column utilizing a butyl (C4) stationary phase bonded to non-porous hydrophilic polymer (methacrylate) particles.

This HIC phase is specifically designed for fast, high-resolution separations of proteins and biopharmaceutical drugs such as monoclonal antibodies (mAbs), including drug-to-antibody ratio (DAR) analysis of antibody-drug conjugates (ADCs).

YMC BioPro HIC BF has been used with successful results on several commercially available mAb drugs with a run time of under 15 minutes.

The high resolution and good peak shape offered by YMC's BioPro HIC BF material enables the detection of small impurities that could be missed when using other phases. Additionally, the use of isopropanol as a modifier helps reduce retention times of highly hydrophobic compounds and is useful for adjusting selectivity and achieving higher recovery.

Click here to read more about YMC BioPro HIC BF.

Visit the YMC America website at https://www.ymcamerica.com/ to view all analytical columns available for sale. Contact a YMC America representative by email at info@ymcamerica.com or by calling 888-341-8380 today.

About YMC
YMC is a private life science company headquartered in Kyoto, Japan. Founded in 1980, YMC has 9 affiliates and facilities in Asia, Europe, and the Americas. Over 500 YMC employees are providing best-in-class lab and process solutions to bio/pharmaceutical industry.

YMC delivers and supports these solutions in all major global geographies on six continents.

YMC's focus is on innovation, production, and sales of packing materials, packed columns, and systems for High Performance Liquid Chromatography (HPLC), Low Pressure Liquid Chromatography (LPLC) and custom purification and custom synthesis.

YMC operates a CMO facility and pilot plant incorporating state of the art simulated moving bed (SMB) purification.

YMC America has been in operation over 30 years serving the Americas. In 2019, YMC acquired the former LEWA Process Technologies (Devens, MA USA) and ChromaCon AG (Zurich, CH).

YMC's intellectual properties, cultivated from many years of experience, will continue to push the limits to create a prosperous future for purification and discovery of small and large molecule therapies.

See: https://www.ymcamerica.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Devens, MA -- (SBWIRE) -- 03/04/2021 -- YMC's three-page Application Note highlights the practical steps of method development and scale up for the reversed-phase LC purification of the therapeutic peptide, liraglutide. The Application Note is entitled: Purification of Peptides with Full Flexibility.

Purification is a critical step in devising a cost-effective manufacturing process for peptide therapeutics — the goal being the optimized combination of loadability, recovery, and purity.

The method for the purification of liraglutide (antidiabetic peptide marketed by Novo Nordisk as Victoza®) achieved high resolution using YMC-Triart Prep C18-S under alkaline conditions. The purity obtained for the target compound was 99.5 percent.

Separation of the crude sample appeared to be successful at low to neutral pH, but a co-eluting peak emerged at pH 6.5, and the impurity was resolved at pH 8.5.

Developing a method for peptide purification at pH 8.5 can be difficult due to the instability of typical reversed-phase media at a higher pH. YMC-Triart is a hybrid reversed-phase material that tolerates pH 8.5 (and higher) for the extended/continuous periods required in a manufacturing purification process.

Because of its stability at high pH, YMC-Triart was an ideal choice for scouting during method development, and YMC-Triart was also an ideal choice for production-scale purification of this peptide.

The Application Note shows example chromatograms, as well as the scale-up calculations for liraglutide purification up to over 750 g of peptide per day.

Contact info@ymcamerica.com or call 888-341-8380 to get in touch with a YMC America representative.

About YMC
YMC is a private life science company headquartered in Kyoto, Japan. Founded in 1980, YMC has 9 affiliates and facilities in Asia, Europe, and the Americas. Over 500 YMC employees are providing best-in-class lab and process solutions to bio/pharmaceutical industry.

YMC delivers and supports these solutions in all major global geographies on six continents.

YMC's focus is on innovation, production, and sales of packing materials, packed columns, and systems for High Performance Liquid Chromatography (HPLC), Low Pressure Liquid Chromatography (LPLC) and custom purification and custom synthesis.

YMC operates a CMO facility and pilot plant incorporating state of the art simulated moving bed (SMB) purification.

YMC America has been in operation over 30 years serving the Americas. In 2019, YMC acquired the former LEWA Process Technologies (Devens, MA USA) and ChromaCon AG (Zurich, CH).

YMC's intellectual properties, cultivated from many years of experience, will continue to push the limits to create a prosperous future for purification and discovery of small and large molecule therapies.

See: https://www.ymcamerica.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

PeptiDream and YMC groups announce a formal joint-task group to scale successful lab work to multiple GMP production lines for specialty peptide drug products at the main factory of PeptiStar Inc. YMC’s patented twin-column technology will be a key technology in the venture. Work is anticipated to result in the implementation of the technology on a large scale in late 2021.

Devens, MA -- (SBWIRE) -- 03/04/2021 -- YMC CO., LTD. (YMC) has formalized a joint-study to scale continuous chromatography technology to the purification process at mass production scale of peptide-based therapeutic drugs with PeptiDream Inc. and PeptiStar Inc. PeptiDream Inc. and PeptiStar Inc. are developers and manufacturers of specialty peptide therapeutics. Extensive lab studies using YMC's twin-column continuous chromatography technology showed great improvement in the productivity of these highly valuable drug substances. Further studies will be conducted at the main factory of PeptiStar Inc. (Settsu, Osaka), where the same technology proven at research scale will be implemented on a production scale system designed for GMP manufacturing. YMC expects to have a full-start of the industrial scale work by the end of 2021.

The joint-study group is presently using the lab results at PeptiStar for further optimization of a GMP compliant larger scale twin-column continuous chromatography system, known as "Contichrom TWIN." There are multiple production lines for specialty peptide drugs at the main factory of PeptiStar Inc. (PeptiDream Inc. is a key investor in PeptiStar Inc.). Currently, conventional single-column chromatography systems are used in all purification processes. This will be the first case in Japan for both YMC and PeptiStar/PeptiDream for multi-column purification technology at production scale.

YMC has significantly increased resources for the development of continuous chromatography technology used in the preparative purification process of smaller drug molecules such as peptides and nucleic acids, as well as larger antibody drugs for the biopharmaceutical industry. Following the take-over of the related business from LEWA-Nikkiso America, Inc. in 2018, YMC gained twin-column continuous chromatography systems for research and for industrial use, which enable recovery of the target object in high efficiency and high purity, by purchasing ChromaCon AG (Zurich) in April 2019. YMC also manufactures packing materials and columns, which are essential to these systems.

The continuous chromatography systems attract attention from domestic/international major pharmaceutical companies. While many of those systems for research are already introduced domestically and internationally, the systems for industrial use are also starting to receive orders, including from European and American pharmaceutical companies. Last year, the Food and Drug Administration (FDA) purchased the bench-scale system for the purpose of evaluating the quality of the variety of pharmaceutical products manufactured using a continuous production system.

Visit https://www.ymcamerica.com to learn more or to purchase UHPLC and HPLC columns and other preparative chromatography materials.

About YMC
YMC is a private life science company headquartered in Kyoto, Japan. Founded in 1980, YMC has 9 affiliates and facilities in Asia, Europe, and the Americas. Over 500 YMC employees are providing best-in-class lab and process solutions to bio/pharmaceutical industry.

YMC delivers and supports these solutions in all major global geographies on six continents.

YMC's focus is on innovation, production, and sales of packing materials, packed columns, and systems for High Performance Liquid Chromatography (HPLC), Low Pressure Liquid Chromatography (LPLC) and custom purification and custom synthesis.

YMC operates a CMO facility and pilot plant incorporating state of the art simulated moving bed (SMB) purification.

YMC America has been in operation over 30 years serving the Americas. In 2019, YMC acquired the former LEWA Process Technologies (Devens, MA USA) and ChromaCon AG (Zurich, CH).

YMC's intellectual properties, cultivated from many years of experience, will continue to push the limits to create a prosperous future for purification and discovery of small and large molecule therapies.

See: https://www.ymcamerica.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Devens, MA -- (SBWIRE) -- 02/10/2021 -- Guard columns offer important functions in liquid chromatography. Guard columns protect the analytical column from contamination or damage, resulting in longer column life.

In the process of method development, irreversible retention of some sample components can occur. When a guard column is used, the problem occurs at the guard column, thus protecting the analytical column.

For routine analyses, in addition to helping minimize problems associated with chemistry (i.e., retained compounds), guard columns can also help minimize the impact of physical issues at the head of the analytical column, such as a clogged frit or voiding at the column inlet.

Analytical columns with clogged frits and/or voiding can often be restored with techniques such as reverse flow flushing.

Analytical columns with unwanted retained components can often be restored by cleaning in place (CIP) with a strong solvent. When effective, restoring the performance of a guard column is typically faster and easier than restoring the performance of an analytical column.

It should be noted that reverse-flushing and CIP are time-consuming, and not always completely successful. For this reason, guard columns are designed to be low-cost items that are easily replaced with a minimum of system downtime.

For best performance, the stationary phase and column diameter of the guard column should closely match that of the analytical column. YMC-Triart is a family of stationary phases based on a hybrid base particle and is offered in nine distinct and overlapping phase chemistries — as well as multiple particle sizes. YMC-Triart itself demonstrates excellent tolerance to high pressure, high and low pH, and elevated temperatures.

In addition to a wide selection of stationary phase chemistries, YMC-Triart columns are available in a wide selection of diameters and separation scales: capillary LC, UHPLC, HPLC, Semi-Prep, and Prep. YMC offers guard column solutions for all of them.

Read more about YMC-Triart Guard Columns at https://www.ymcamerica.com/ or contact a YMC America representative at info@ymcamerica.com or 888-341-8380.

About YMC
YMC is a private life science company headquartered in Kyoto, Japan. Founded in 1980, YMC has 9 affiliates and facilities in Asia, Europe, and the Americas. Over 500 YMC employees are providing best-in-class lab and process solutions to bio/pharmaceutical industry.

YMC delivers and supports these solutions in all major global geographies on six continents.

YMC's focus is on innovation, production, and sales of packing materials, packed columns, and systems for High Performance Liquid Chromatography (HPLC), Low Pressure Liquid Chromatography (LPLC) and custom purification and custom synthesis.

YMC operates a CMO facility and pilot plant incorporating state of the art simulated moving bed (SMB) purification.

YMC America has been in operation over 30 years serving the Americas. In 2019, YMC acquired the former LEWA Process Technologies (Devens, MA USA) and ChromaCon AG (Zurich, CH).

YMC's intellectual properties, cultivated from many years of experience, will continue to push the limits to create a prosperous future for purification and discovery of small and large molecule therapies.

See: https://www.ymcamerica.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Devens, MA -- (SBWIRE) -- 02/08/2021 -- YMC's four-page Technical Note provides practical guidance for the development and improvement of methods for peptide purification. The Technical Note is entitled: How to improve a peptide purification process.

The Technical Note lists three critical contributing factors to the development of an efficient peptide purification process — Selectivity, Loadability/Recovery, and Media Lifetime (media stability) — and goes on to provide recommendations regarding each individual aspect.

Selectivity determines the resolution of the separation. The highest purification productivity can be obtained only from a separation with optimal resolution. Therefore, says the Technical Note, it is important to screen different stationary phase chemistries under differing separation conditions.

Loadability and Recovery are obviously at the heart of any purification method. Once again, screening of different stationary phases and variations in conditions will lead the analyst to the most suitable combination of media and conditions. For peptides, choosing a stationary phase with larger diameter pores (i.e., larger than 180A) will generally lead to optimal interaction between the peptide and the surface of the stationary phase. Too large a pore diameter, warns YMC, can lead to poor reproducibility.

The goal of combining Selectivity and Loadability/Recovery is a result where the largest possible fractions can be concentrated and collected in the smallest possible volume, with the lowest contamination by adjacent fractions containing undesired material.

The third contributor to successful peptide purification methods is Media Lifetime, or more accurately, useful Media Lifetime. The lifetime of a stationary phase has an obvious impact on the economics of the preparative purification process. The subtlety in this regard is that the stationary phase needs to remain stable and reproducible during its lifetime. Long life is not useful if the behavior of the material changes as a result of repeated use.

Media Lifetime can be evaluated in terms of mechanical durability (stable when exposed to pressure shock and column re-packing cycles) and chemical stability (ability to withstand pH extremes during use and during alkaline cleaning in place (CIP) conditions).

YMC's Triart reversed-phase materials have been shown to be effective in peptide purification applications and are available in a variety of surface chemistries to address different purification requirements. The YMC-Triart phases are synthesized on a hybrid silica base particle, exhibiting excellent behavior in terms of mechanical and chemical stability.

Contact YMC America by email at info@ymcamerica.com or by phone at 888-341-8380.

About YMC
YMC is a private life science company headquartered in Kyoto, Japan. Founded in 1980, YMC has 9 affiliates and facilities in Asia, Europe, and the Americas. Over 500 YMC employees are providing best-in-class lab and process solutions to bio/pharmaceutical industry.

YMC delivers and supports these solutions in all major global geographies on six continents.

YMC's focus is on innovation, production, and sales of packing materials, packed columns, and systems for High Performance Liquid Chromatography (HPLC), Low Pressure Liquid Chromatography (LPLC) and custom purification and custom synthesis.

YMC operates a CMO facility and pilot plant incorporating state of the art simulated moving bed (SMB) purification.

YMC America has been in operation over 30 years serving the Americas. In 2019, YMC acquired the former LEWA Process Technologies (Devens, MA USA) and ChromaCon AG (Zurich, CH).

YMC's intellectual properties, cultivated from many years of experience, will continue to push the limits to create a prosperous future for purification and discovery of small and large molecule therapies.

See: https://www.ymcamerica.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

YMC plans expansion of lab development services and consolidation of its Allentown, PA, location into its larger Devens, MA, facility. The new location will facilitate an increase in customer services and a larger site staff to support the future growth of consumable products.

Devens, MA -- (SBWIRE) -- 01/06/2021 -- YMC America business operations will relocate to Devens, MA, to add resources, space, and improved access to the epicenter of the global bio/pharma industry.

YMC America, a leading supplier of separation resins, services, and systems for the pharmaceutical market, will expand its operations into the YMC Devens, MA, facility beginning 1 February 2021. This move from its existing location in Allentown, PA, will provide more space for inventory and a larger employee base. The move seeks to retain the majority of YMC America employees.

The YMC Devens, MA, facility is the 32,000 ft2 (2,900 m2) R&D and manufacturing site of the former LEWA Process Technologies, which YMC acquired in 2019.

The YMC Devens location is simultaneously establishing a new lab facility in a recently acquired building adjacent to the current site. This lab facility will support the heritage of YMC America products and serve as a center for conducting short and long-term studies as well as hands-on training.

The YMC Group provides a range of chromatography resins, columns, and services that enable small and large molecule researchers and manufacturers to access a full complement of resources to facilitate the cost-effective production and QC of next-generation drugs. This expansion of capabilities will have a positive impact on customers using YMC technology by bringing closer together the consumable components of YMC (resins, pre-packed columns, related accessories) and the lab/GMP systems manufactured by YMC's Devens bio/pharma systems group.

The addition of the new lab building will enable YMC and YMC customers to evaluate and develop processes using the entire suite of YMC purification products. As an example, the use of leading C18 chemistries (YMC-Triart) has recently proven to further enhance the productivity of novel YMC system technologies such as YMC's patented MCSGP technology for continuous purification of peptides, oligos, RNA- and DNA-based therapies, and vaccines.

This strengthening of capabilities in the Americas builds on YMC's global leadership in continuous separation/purification technology. In Kyoto, Japan, at its recently opened lab complex known as "Kyoto Works," YMC is escalating R&D of the continuous separation/purification platform in parallel with the expansion at the Devens location.

The YMC Group intends to accelerate the development of the continuous separation/purification business on a global basis by leveraging its manufacturing, R&D, and laboratory infrastructures in Japan, Europe, and the Americas.

About YMC Co., Ltd.
YMC is a private life science company headquartered in Kyoto, Japan. Founded in 1980, YMC has 9 affiliates and facilities in Asia, Europe, and the Americas. Over 500 YMC employees are providing best-in-class lab and process solutions to the bio/pharmaceutical industry.

YMC delivers and supports these solutions in all major global geographies on six continents.

YMC's focus is on innovation, production, and sales of packing materials, packed columns, and systems for High-Performance Liquid Chromatography (HPLC), Low Pressure Liquid Chromatography (LPLC), and custom purification and custom synthesis.

YMC operates a CMO facility and pilot plant incorporating state of the art simulated moving bed (SMB) purification.

YMC America has been in operation for over 30 years serving the Americas. In 2019, YMC acquired the former LEWA Process Technologies (Devens, MA USA) and ChromaCon AG (Zurich, CH).

YMC's intellectual properties, cultivated from many years of experience, will continue to push the limits to create a prosperous future for purification and discovery of small and large molecule therapies.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

GMP-scale system enables advanced purification of peptides, oligos, RNA, and dsDNA based therapies and vaccines on a continuous basis.

Allentown, PA -- (SBWIRE) -- 12/21/2020 -- A state-of-the-art lab, with a focus on developing continuous purification technologies, that was inaugurated in November 2019 will be home to the first-of-a-kind continuous HPLC. Named "Kyoto Works," the 2,600m² facility is owned by YMC in Fukuchiyama, near Kyoto, Japan.

The lab is now readying to accept a production scale Contichrom TWIN 300 HPLC enabled with the patented multi-column countercurrent solvent gradient purification (MCSGP) technology. This twin-column HPLC system is the largest of its kind in the world and will be available for customer use as well as in-house development work. It joins the multiple Contichrom CUBE bench top units, which have the MCSGP functionality, already in use at the Kyoto Works facility. Uniquely, the unit is engineered to operate both as an HPLC designed to 100 bar as well as perform LPLC tasks such as ion-exchange chromatography. A smaller-scale pilot GMP unit is available in the USA.

Using the proprietary semi-continuous chromatographic process of MCSGP, users report 30-60% gains in yield while reducing solvent consumption up to 70% during purification of peptides and oligos. The MCSGP process works by automatically alternating the feeding of one of two identical columns while eluting the other column. The automatic internal recycling maintains the high product purity while purifying a much greater percentage of valuable product from a feed solution.

In its inaugural year, the YMC Kyoto Works lab is operating in Phase I of a multiple phase roll out of capabilities. In Phase I, the facility has lab to mid capacity DAC (dynamic axial compression) column manufacturing (300~600?) and houses three (3) Contichrom CUBE instruments, an EcoPrime six (6) column simulated moving bed (SMB) HPLC, an SMB lab instrument, a Contichrom TWIN CaptureSMB 100 GMP scale LPLC, and a 1000?DAC system.

The TWIN MCSGP unit adds its 0.3 to 3.3 LPM capacity to the already impressive array of technologies available in the YMC Kyoto Works. Phase II of Kyoto Works lab will see up to 200 employees with manufacturing capacity, and an additional building (explosion-proof/GMP) is planned for completion in 2021 on the 52,000 m² of YMC owned land.

"The addition of another of YMC's patented twin-column technology to our Kyoto Works facility at the GMP scale signals further commitment to enabling our customers access to continuous purification of vaccines and therapies," says Ryuji Yamamura, CEO of YMC. "Since the acquisition of ChromaCon AG in 2019, YMC has quickly brought the technology of continuous chromatographic processes to market at production scale through internally funded investment. YMC's commitment to bring this scale to industrial manufacturing processes is core to our mission and continues our heritage as a pioneer in chromatography. The user of such systems will gain substantial leverage in producing new therapies at cost-effective quantities. Further, the owners will be reducing environmental concerns by using far less solvents — an attractive benefit in the reduction of greenhouse gases."

Recently the USA's FDA acquired YMC's twin-column technology for evaluation, and a major GMP producer in the EU has placed orders for two (2) larger versions of the Contichrom TWIN HPLC MCSGP enabled systems. These units are scheduled for GMP production of peptides and oligo based drugs in early 2021.

The Contichrom TWIN units are manufactured in the USA at YMC's Center of Excellence for GMP scale systems in Devens, MA, where other pilot scale units are available for customer evaluation. The capability to manufacture the same systems is being developed in YMC's Japanese manufacturing sites.

The YMC Contichrom TWIN HPLC system enabled with the patented MCSGP technology now is seen to have tremendous economic benefits to the emerging DNA/RNA based drugs and vaccines as indicated in recent studies at the bench, which has piqued the interest of those working with novel RNA and DNA approaches to COVID vaccines. The rapid uptake of this technology and the additional insights gained at Kyoto Works bodes well for the future of this and other YMC products.

Visit https://www.ymcamerica.com/ to learn more about YMC's state-of-the-art lab and to purchase UHPLC and HPLC columns, or speak with a YMC America representative by emailing info@ymcamerica.com or calling 888-341-8380.

About YMC America, Inc.
Established in 1980, YMC America, Inc. is worldwide full-service liquid chromatography company, which offers sales, technical product support, service, application assistance, purification services, contract synthesis and method development.

All YMC products are available worldwide through YMC's network of subsidiaries. This worldwide presence as a full-range chromatography supplier ensures that all YMC products are fully available and fully supported both locally and globally.
See: https://www.ymcamerica.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Allentown, PA -- (SBWIRE) -- 12/15/2020 -- Anyone faced with the challenges of isolating biomolecules such as mAbs, intact proteins, peptides, nucleotides, antibody drug conjugates (ADCs), or oligosaccharides, is also faced with the challenge of making the most optimal choice for their method and mode of separation.

Most LC separations involving biomolecules can be performed using one of four main chromatographic modes: reversed-phase, ion exchange, size exclusion, and hydrophobic interaction. Factors such as sample matrix, sample size, and goal of the separation influence which choice is best.

Across the broad range of possible separation types, the advantages and disadvantages of each mode are oftentimes overlapping, which clouds the decision path for optimizing LC separations of biomolecules.

In response to this, YMC has developed guidance for optimal column selection on its website, providing information and examples of stationary phase options for bioseparations.

The purpose of YMC's Bioseparations Guide is to make it easier for bio-focused customers to find the correct column for their separation, first by winnowing out the choices that aren't pertinent, and then by presenting options, supporting data, and example chromatograms.

Click here to view the Biomolecule Guide page on the YMC website.

The Guide presents the various column/phase choices by MODE: IEX/HIC, Size Exclusion, and Reversed-Phase.

After choosing the appropriate mode, the various choices for stationary phases are laid out. YMC America offers columns, bulk material/resin, and screening kits. Analytical scale separations, and scale-up to prep, are supported.

YMC application examples are included throughout. These will serve to guide users to the optimal choice(s) based on the application.

Visit YMC America now to learn more about biomolecule separation or to purchase analytical, UHPLC, and HPLC columns online. Contact info@ymcamerica.com or call 888-341-8380 for more information.

About YMC America, Inc.
Established in 1980, YMC America, Inc. is worldwide full-service liquid chromatography company, which offers sales, technical product support, service, application assistance, purification services, contract synthesis and method development.

All YMC products are available worldwide through YMC's network of subsidiaries. This worldwide presence as a full-range chromatography supplier ensures that all YMC products are fully available and fully supported both locally and globally.
See: https://www.ymcamerica.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Allentown, PA -- (SBWIRE) -- 11/27/2020 -- CHIRAL ART Cellulose-SZ is a new chiral stationary phase recently launched by YMC. It is the seventh phase in the CHIRAL ART family of polysaccharide chiral phases for HPLC.

Chiral phases are used for the separation of stereoisomers and enantiomers – analytes that are otherwise difficult to separate using widely used modes such as reversed-phase, size exclusion, or ion exchange. But not all chiral phases perform well with all molecules of this type. Hence, access to a variety of chiral selectors is useful when working on a new separation challenge or improving an old one.

The CHIRAL ART family of chiral phases includes five different chiral selectors. All five selectors – including Cellulose-SZ – are available as immobilized type; two selectors are also available in coated type.

The immobilized type of chiral selector does not change the chemistry of the selector, but it does enable the use of a wider range of solvents, making them stable in both normal phase mode and reversed phase mode.

The new CHIRAL ART Cellulose-SZ selector is cellulose tris(3-chloro-4-methylphenylcarbamate). Its stereoselectivity is complementary to the other cellulose tris and amylose tris selectors used in the other CHIRAL ART phases.

CHIRAL ART Cellulose-SZ performs well in a wide range of pH conditions from pH 2 to pH 10. It is also resistant to and stable in a wide range of solvents, showing little or no decline in performance after repeated flushing cycles with solvents such as ethyl acetate, tetrahydrofuran, and dichloromethane.

CHIRAL ART Cellulose-SZ is available in 3µm and 5µm particle sizes as well as various column lengths and diameters suitable for SFC and HPLC, and scalable from analytical to prep.

Columns offered are suitable for supercritical fluid chromatography (SFC) and simulated moving bed (SMB) separations, as well as conventional HPLC.

Learn more here.

Contact info@ymcamerica.com or call 888-341-8380 for more information or to purchase chiral columns, HPLC columns, and more.

About YMC America, Inc.
Established in 1980, YMC America, Inc. is worldwide full-service liquid chromatography company, which offers sales, technical product support, service, application assistance, purification services, contract synthesis and method development.

All YMC products are available worldwide through YMC's network of subsidiaries. This worldwide presence as a full-range chromatography supplier ensures that all YMC products are fully available and fully supported both locally and globally. See: https://www.ymcamerica.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Allentown, PA -- (SBWIRE) -- 11/24/2020 -- YMC has recently developed a YMC-Triart phase specifically designed for medium and large-scale purification of insulin and other peptides. This new stationary phase is described in a new technical flyer from YMC America.

YMC-Triart Prep Bio200 C8 is an extension of the YMC-Triart product line that shares the fundamental advantages of the YMC-Triart hybrid base particle. YMC included certain product features designed specifically to improve results with insulin/peptide purification.

The novel inorganic/organic hybrid silica is common to all the YMC-Triart phases.

The flyer reviews the importance of the physical strength of YMC-Triart media. The results of a YMC study reveal little change in column pressure even after repeated packing-unpacking-repacking cycles. This is evidence of the mechanical durability of the material, as few fines are created during packing and unpacking.

Mechanical durability also contributes to the successful use of Triart Prep Bio200 C8 with dynamic compression columns — most typically, dynamic axial compression [DAC] columns. Dynamic compression applies pressure to the packed bed to keep it uniformly organized, but the pressure can damage – literally fracture – conventional silica-based phases. This can lead to increases in column backpressure and degradation of separation performance.

The flyer also shows a second important advantage of YMC-Triart Prep Bio200 C8: chemical stability. The media is stable at any pH between 1 to 10 (regular use) and up to pH 12 for clean-in-place. This stability facilitates the use of alkaline (or acidic) cleaning in place (CIP) protocols at extreme pH that would be too harsh for conventional media. The flyer shows the results of a test involving 300 cycles of alkaline CIP.

The flyer also discusses two additional properties of YMC-Triart Prep Bio200 C8 as they relate specifically to peptide purification.

By using shorter chain C8 (USP designation L7) stationary phase chemistry, YMC-Triart Prep Bio200 C8 is measurably less retentive than C18 (ODS) materials often used for peptide purification. This provides reduction of fraction volume and can help reduce time spent performing post chromatography processes such as condensation and lyophilization.

The second characteristic is that YMC-Triart Prep Bio200 C8 has a particle pore size of 200A. Typical pore size for reversed-phase media is 120A – this can be too small for good results with peptide molecules of 5-50 amino acids. On the other hand, a pore size of 300A, generally considered useful for proteins and intact antibodies, is larger than optimal for peptide purification.

For a copy of the technical flyer, contact info@ymcamerica.com or call 888-341-8380.

About YMC America, Inc.
Established in 1980, YMC America, Inc. is worldwide full-service liquid chromatography company, which offers sales, technical product support, service, application assistance, purification services, contract synthesis and method development.

All YMC products are available worldwide through YMC's network of subsidiaries. This worldwide presence as a full-range chromatography supplier ensures that all YMC products are fully available and fully supported both locally and globally. See: https://www.ymcamerica.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Allentown, PA -- (SBWIRE) -- 11/04/2020 -- The YMC product line for biomolecule separations is covered in a 24-page Bioseparation brochure, available for download below.

YMC has amassed many choices for HPLC of biomolecules, including reversed-phase, size exclusion (SEC), hydrophilic interaction (HILIC), hydrophobic interaction (HIC), and ion exchange (IEX). All are covered in the brochure; the presentation includes comparisons of results achievable using different modes of separation.

The 24-page brochure presents information about columns, phases, hardware systems, and other items of interest in biomolecule research and purification. Products for lab scale research are included, as well as production scale prep – helping customers map a scale-up path.

The brochure begins with two column selection guides: one for proteins and peptides, and another for nucleic acids. Both guides offer useful summaries of the considerations for evaluating and choosing the mode of separation best suited to the application.

The brochure details how biomolecules can be analyzed via IEX, reversed-phase, SEC, HILIC, and HIC, as well as what type of information can be obtained from each of these chromatographic modes. The brochure shows results for separation of human serum, mouse monoclonal IgG1, mouse IgG Fc fragment, sugar chains, nucleic acids, oligonucleotides, and more.

YMC offers pre-packed IEX columns in PEEK column hardware with PEEK end fittings. For columns that operate under higher pressures – such as reversed-phase columns for bioseparations – YMC offers stainless steel columns, as well as PEEK-lined stainless steel columns, complete with PEEK frits for an inert separation environment.

Hardware systems, including preparative scale LC systems and glass columns, are also described.

Read the YMC Bioseparations brochure here.

Interested parties can purchase HPLC and UHPLC columns online at https://www.ymcamerica.com/. Contact info@ymcamerica.com or call 888-341-8380 for more information.

About YMC America, Inc.
Established in 1980, YMC America, Inc. is worldwide full-service liquid chromatography company, which offers sales, technical product support, service, application assistance, purification services, contract synthesis and method development.

All YMC products are available worldwide through YMC's network of subsidiaries. This worldwide presence as a full-range chromatography supplier ensures that all YMC products are fully available and fully supported both locally and globally.
See: https://www.ymcamerica.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Allentown, PA -- (SBWIRE) -- 10/27/2020 -- YMC-Triart is a well-established family of stationary phases for reversed-phase HPLC. The phases are based on an organic-inorganic hybrid silica particle and are available in pre-packed columns or bulk supply.

Although reversed-phase separation is often thought of as ideal for small molecules, biochromatographers are successfully using reversed-phase mode for separation involving amino acids, peptides, and even intact proteins and antibodies.

Since the introduction of YMC-Triart C18 over a decade ago, YMC has added additional phases with larger particle sizes for large scale separations, phases with larger pore sizes for better separation of large molecules, and different phase chemistries for different separation selectivity.

New reversed-phase materials offer some advantages for medium and large-scale separation of peptides. YMC cites their YMC-Triart Prep Bio200 C8 phase as having a pore size (200 A) that is well-suited for medium to large peptides, and a shorter chain octyl (C8) group that is lower in hydrophobicity compared to C18. YMC cites peptide separations showing sharper peaks due to the larger pore size and smaller fraction volumes due to the compressed separation.

Today, the YMC-Triart product family presents an opportunity for research and development teams to map separation scale-up from the lab bench to the pilot stage and on to full production.

The YMC-Triart product range is structured so that users can scale-up on what is essentially the same material, just a different particle size. The company points to savings in time and energy that otherwise is often wasted in adjustments at each step along the scale-up process. With Triart, selectivity remains the same across all particle sizes.

The hybrid particle, and the bonded stationary phases themselves, exhibit mechanical and chemical stability, and are able to endure extreme pH, high backpressure, and elevated temperature.

The ability to remain stable under stresses of pH, pressure, and temperature, enables greater flexibility in the choice of separation conditions, including some conditions, according to YMC, that improve separation results but might not be practical with conventional phases. (For example: high pH)

YMC-Triart is available with eight different bonded phases, including C4, C8, Diol-HILIC, PFP, Phenyl, and three variants of C18. Two of the phases (C4 and C18) are offered with a larger (300A) pore size to improve the separation of larger molecules. Triart phases are available in 1.9µm particle size for UHPLC, and up to 20µm particle diameter for semi-prep, polishing, and manufacturing scale separations.

To shop UHPLC columns and analytical columns, visit the YMC America website at https://www.ymcamerica.com. For additional information, contact info@ymcamerica.com or call 888-341-8380 to speak with a YMC America representative.

About YMC America, Inc.
Established in 1980, YMC America, Inc. is worldwide full-service liquid chromatography company, which offers sales, technical product support, service, application assistance, purification services, contract synthesis and method development.

All YMC products are available worldwide through YMC's network of subsidiaries. This worldwide presence as a full-range chromatography supplier ensures that all YMC products are fully available and fully supported both locally and globally. See: https://www.ymcamerica.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Allentown, PA -- (SBWIRE) -- 09/14/2020 -- YMC America describes a size exclusion chromatography column in a 2-page brochure. The column is optimized for aggregates and fragments of monoclonal antibodies (mAb).

YMC-SEC MAB utilizes a dihydroxypropyl stationary phase bonded to a silica gel base. The particle size is 3 µm, and the pore size is 250A.

Because of the particle size and pore size of the column, YMC-SEC MAB is able to separate aggregates from the mAb monomer and also resolve lower molecular weight mAb fragments.

YMC-SEC MAB is useful across a wide molecular weight range, from 10kDa to 700kDa, to be exact.

YMC-SEC MAB is recommended for SEC analysis of antibody-drug conjugates using organic-containing mobile phases.

The columns characteristically show high reproducibility lot-to-lot and long useful lifetime. They are ideal for both research and quality control applications.

A column durability test displayed in the flyer illustrates no meaningful performance degradation after more than 500 injections (monoclonal antibody analysis).

The flyer also documents the lot-to-lot reproducibility of the columns and shows separations of humanized monoclonal antibody (mAb) and antibody-drug conjugate (ADC).

Read more about YMC-SEC MAB here.

Contact YMC America by email at info@ymcamerica.com or call their direct line at 888-341-8380 to obtain a copy of the YMC-SEC MAB flyer or to buy columns.

About YMC America, Inc.
Established in 1980, YMC America, Inc. is worldwide full-service liquid chromatography company, which offers sales, technical product support, service, application assistance, purification services, contract synthesis and method development.

All YMC products are available worldwide through YMC's network of subsidiaries. This worldwide presence as a full-range chromatography supplier ensures that all YMC products are fully available and fully supported both locally and globally. See: https://www.ymcamerica.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Allentown, PA -- (SBWIRE) -- 09/09/2020 -- YMC Chiral columns include traditional Polysaccharide phases (Amylose and Cellulose) as well as Cyclodextrin phases and specialty chiral phases such as NEA and SumiChiral.

Columns packed for prep, analytical, or guard column use are available.

YMC Chiral phases can be found in 3, 5, 10, 20, and 50-micron particle sizes — suitable for high-resolution analytical separations on up to production scale purification.

YMC Chiral ART columns (and bulk materials) utilize conventional Amylose and Cellulose Polysaccharide-based phases. YMC Chiral ART Polysaccharide phases exhibit high stereoselectivity and familiar separation behavior. YMC Chiral ART columns can be used for separations of a wide range of chiral compounds, cis-trans isomers, and geometric isomers.

YMC Chiral ART Polysaccharide phases provide traditional, familiar separations:

· Coated Phase — low initial cost and high durability.
· Immobilized Phase — the immobilized phase enables the use of a wider range of solvents.

For prep/purification applications, YMC Chiral ART materials exhibit high durability and high performance even after repeated re-packings.

YMC Cyclodextrin Chiral Phases include three types of bromo-cyclodextrin phases and two phases specifically for preparative isolation of optical isomers. The bromo-cyclodextrin phases can be used effectively alone or in conjunction with reversed-phase media.

YMC NEA (R) and (S) Chiral Phases are chiral polymer-bonded silica gel used for optical isomer separation. Chiral discrimination is based upon the higher-order structure of chiral macromolecules that includes hydrogen bonding, p-p interaction, hydrophobic interaction, etc.

On YMC SUMICHIRAL OA columns, direct separation of various enantiomers can be realized. Enantiomeric separation is achieved via the various diastereomeric interactions such as hydrogen bonding, charge transfer, and host-guest interactions. The columns are offered in Improved Pirkle Type, Ligand Exchange Type, and Host-Guest Type.

Download a copy of the YMC Chiral ART brochure here.

Visit YMC America to learn more about Chiral Separation products and buy columns, or use YMC's phase selector page at https://www.ymcamerica.com/product-page-columns-by-phase/

Also, contact info@ymcamerica.com or call 888-341-8380.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Allentown, PA -- (SBWIRE) -- 08/06/2020 -- YMC-Triart recently published application information showing the successful separation of Diphenhydramine, Lidocaine, and 4-Isopropyl-3-methylphenol by reversed-phase.

The analytes of interest are components of a commercial anti-itch medication. Separation under acidic or neutral conditions proved difficult, due to either co-elution or poor resolution.

YMC's application shows optimal peak separation and peak shape using YMC-Triart C18 Hybrid Column under alkaline (pH 9.6) gradient mobile phase conditions. Further study resulted in an isocratic solution, also at pH 9.6. In both the gradient analysis and the isocratic analysis, separation of the analytes of interest – without interference from compound additives and formulation artifacts – was achieved.

Enabling the separation is the combination of alkaline pH and slightly elevated temperature (37°C). YMC-Triart C18 Hybrid Columns perform successfully under the combined conditions of high pH and elevated temperature. YMC-Triart C18 is stable at pH as high as 12 and temperatures up to 50°C (up to 90°C, at pH 7 and lower).

The separation is completed in under 8 minutes for the gradient analysis and under 6 minutes for the isocratic conditions. Conditions are conventional HPLC conditions: 1.0 mL/min flowrate, a 4.6 x 150 mm column, and stationary phase particle size of 3 µm.

Additional information can be found here.

To learn more or purchase YMC-Triart C18 Hybrid columns and other HPLC columns, please contact YMC America by email at info@ymcamerica.com or by calling 888-341-8380.

About YMC America, Inc.
Established in 1980, YMC America, Inc. is worldwide full-service liquid chromatography company, which offers sales, technical product support, service, application assistance, purification services, contract synthesis and method development.

All YMC products are available worldwide through YMC's network of subsidiaries. This worldwide presence as a full-range chromatography supplier ensures that all YMC products are fully available and fully supported both locally and globally. See: https://www.ymcamerica.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Allentown, PA -- (SBWIRE) -- 07/30/2020 -- YMC America describes Minichrom™ BioPro columns in a new two-page brochure. Minichrom™ BioPro columns are polypropylene LC columns packed with YMC BioPro IEX stationary phase material.

The brochure describes how these columns are ideal for use in various bench-scale purification, cleanup, and method development applications involving biomolecules. The content of the brochure goes on to disclose the available column sizes and the specifications of BioPro IEX packing materials.

Specifically indicated in the brochure, Minichrom™ BioPro Columns are available in a range of inner diameters (5, 8, and 11.3 mm) and bed lengths (10, 20, 50, and 100 mm) to accommodate a range of scales and sample sizes. The BioPro IEX resins used in the columns may be either quaternary amino SAX (BioPro Q) or sulfobutyl SCX (BioPro S).

The brochure states that the columns are packed with 20, 30, or 75-micron IEX particles, and are useful in a variety of biomolecule screening, prep, cleanup, purification, and polishing applications.

The Minichrom™ BioPro ion exchange columns are well-suited for IEX separations of peptides, intact proteins, mAbs and other antibodies, nucleotides, nucleosides, and other biomolecules.

Tabular information in the brochure shows the high recovery observed for Ribonuclease A, Cytochrome c, and Lysozyme.

As indicated in the brochure, no special LC hardware is needed. Any low-pressure pump or MPLC system will perform well, as will most typical HPLC systems. The columns are also durable, with the packing material stable at a wide range of pH.

Minichrom™ BioPro Columns can be used, cleaned, stored, and re-used in different applications.

Click here to read the brochure.

Minichrom™ is a trademark of Repligen Corporation.

For more information, contact YMC America by email at info@ymcamerica.com or by phone at 888-341-8380.

About YMC America, Inc.
Established in 1980, YMC America, Inc. is worldwide full-service liquid chromatography company, which offers sales, technical product support, service, application assistance, purification services, contract synthesis and method development.

All YMC products are available worldwide through YMC's network of subsidiaries. This worldwide presence as a full-range chromatography supplier ensures that all YMC products are fully available and fully supported both locally and globally. See: https://www.ymcamerica.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Allentown, PA -- (SBWIRE) -- 07/23/2020 -- YMC-Triart is a widely-used family of stationary phases for HPLC and Prep LC. YMC America has recently developed a YMC-Triart phase specifically designed for medium and large-scale purification of peptides.

The new stationary phase – under the name YMC-Triart Prep Bio200 C8 – is an extension of the YMC-Triart product line that inherits the fundamental advantages of the YMC-Triart hybrid base particle. In addition, YMC integrated certain features designed to improve results specifically for peptide purification.

All YMC-Triart phases begin with the same type of novel inorganic/organic hybrid silica. This hybrid particle technology offers two important advantages to users involved in small or large production scale peptide purification.

First, every YMC-Triart stationary phase, including YMC-Triart Prep Bio200 C8, is mechanically stable and physically strong. This means that the media can be expected to endure repeated column packing, unpacking, and re-packing cycles with minimal particle fracturing. Particle fractures (fines) are common with conventional silica-based media, contributing to increased back-pressure, and sometimes creating voids in the packed bed of media inside the column. YMC-Triart media overcome the weakness that is the principal cause of particle fracturing.

The physical strength of YMC-Triart media also leads to performance improvements in the use of dynamic compression columns (most typically, dynamic axial compression (DAC) columns). Dynamic compression applies pressure to the packed bed to keep it uniformly organized. Bed uniformity is critical to the sharpness of eluted fractions and reducing fraction volume.

The second important advantage of YMC-Triart Prep Bio200 C8 is its chemical stability. The media is stable at any pH from 1 to 10 for regular use and up to pH 12 for clean-in-place. This stability enables the use of alkaline (or acidic) cleaning in place (CIP) protocols at extreme pH that would be too harsh for conventional media. The use of CIP protocols is important in peptide purification to reverse the deterioration of media performance caused by the adsorption of proteins.

YMC also incorporated two important adjustments to the properties of YMC-Triart Prep Bio200 C8.

By using shorter chain C8 (USP designation L7) stationary phase chemistry, YMC-Triart Prep Bio200 C8 is measurably less retentive than C18 (ODS) materials often used for peptide purification. This has the effect of shortening fraction elution times in the peptide purification process.

A second adjustment is that YMC-Triart Prep Bio200 C8 has a particle pore size of 200A. Typical pore size for reversed-phase media is 120A. By fabricating YMC-Triart Prep Bio200 C8 with a 66% larger pore size, the media enables more consistent media surface interaction by peptide molecules of 5-50 amino acids. Consistent and reproducible media interaction is a key factor contributing to low volume elution of purified fractions. A pore size of 300A, generally considered useful for proteins and intact antibodies, is larger than optimal for peptide purification.

To learn more or buy columns, contact YMC America by email at info@ymcamerica.com or call 888-341-8380.

About YMC America, Inc.
Established in 1980, YMC America, Inc. is worldwide full-service liquid chromatography company, which offers sales, technical product support, service, application assistance, purification services, contract synthesis and method development.

All YMC products are available worldwide through YMC's network of subsidiaries. This worldwide presence as a full-range chromatography supplier ensures that all YMC products are fully available and fully supported both locally and globally. See: https://www.ymcamerica.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Allentown, PA -- (SBWIRE) -- 07/21/2020 -- Glass Columns are used regularly by labs requiring lab-scale purification and other applications for LC separations involving large sample volumes. YMC has published a how-to guide providing guidance to users for optimal success in packing glass columns for lab use.

Applications include cleanup of natural products, purification of recombinant products, fraction collection of digested proteins, and much more. Mode of separation can be reversed-phase or normal phase. Mobile phases can be primarily aqueous or organic.

Glass columns have the advantage of being inherently re-packable, reconfigurable for bed length, and swappable for bed diameter. Operated by a low-cost pump, and, in some cases, gravity, glass columns also require only a small investment in equipment and an even smaller investment in equipment maintenance.

Optimal use of glass columns leverages a disciplined packing protocol involving three critical steps: column and media preparation, column packing, and finished column qualification.

YMC's Guide to Packing a Lab Scale Glass Column specifically applies to the YMC ECO and ECO-PLUS glass column product line, but the principles described in the step-by-step guide can be applied to other glass column brands as well.

YMC is primarily known for its line of HPLC phases and pre-packed columns. YMC is also a leading global supplier of separation media and glass columns, with a long history of experience in large scale separations in columns of all types, including the ECO and ECO-PLUS glass columns.

YMC shares its glass column packing expertise in this step-by-step guide. Importantly, the guide begins with column prep, column sizing considerations, calculation of bed volume (and material volume). The column packing section is the most extensive, with 44 detailed steps to ensure that the bed is, among other things, uniformly packed and free of air. The final step of qualification is discussed with a goal of reproducibility.

The Guide to Packing a Lab Scale Glass Columns also includes guidance for successful column un-packing, so that the stationary phase material or gel can be removed and stored without mechanical or chemical compromise.

Contact YMC America by email at info@ymcamerica.com or phone at 888-341-8380 for any further questions.

About YMC America, Inc.
Established in 1980, YMC America, Inc. is worldwide full-service liquid chromatography company, which offers sales, technical product support, service, application assistance, purification services, contract synthesis and method development.

All YMC products are available worldwide through YMC's network of subsidiaries. This worldwide presence as a full-range chromatography supplier ensures that all YMC products are fully available and fully supported both locally and globally.

See: https://www.ymcamerica.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Allentown, PA -- (SBWIRE) -- 06/30/2020 -- Minichrom™ BioPro Columns are polypropylene LC columns filled with YMC BioPro IEX stationary phase material. The columns are ideal for use in various bench-scale purification, cleanup, and method development applications involving biomolecules.

Minichrom™ BioPro Columns are available in a range of inner diameters and bed lengths to accommodate various scales and sample sizes. The BioPro IEX resins used in the columns may be either quaternary amino SAX (BioPro Q) or sulfobutyl SCX (BioPro S).

Packed with 20, 30, or 75-micron IEX particles, Minichrom™ BioPro columns are useful for:

- Bench-scale resin screening and method development
- Bench-scale sample screening
- Bench-scale sample prep/cleanup
- Bind-and-recover sample purification
- Flow-through purification

YMC BioPro Q is a strong anion exchanger (SAX), and YMC BioPro S is a strong cation exchanger (SCX). These phases are suitable for IEX separations of nucleotides, nucleosides, peptides, mAbs and other antibodies, intact proteins, and other biomolecules.

- Regardless of flow rate, YMC BioPro phases display high dynamic binding capacity (DBC).
- YMC BioPro demonstrates superior resolution, low nonspecific adsorption (secondary interactions), and high recovery.
- YMC BioPro is useful for biomolecule purifications due to its high loadability and excellent recovery characteristics.

No special LC hardware is needed. Minichrom™ BioPro Columns use 1/16 inch tubing with finger-tight 10-32 female fittings. The maximum working pressure is 30 bar (435 psi). Any low-pressure pump or MPLC system will perform well, as will most typical HPLC systems.

YMC BioPro 20, 30, and 75-micron materials are extremely durable — with the quaternary amino or sulfobutyl phase bonded to a sturdy polymer base particle. BioPro is stable at any pH from 2-12 and is suitable for rigorous cleaning-in-place (CIP) procedures.

The polypropylene column can be used at any pH (1-14) and is compatible with aqueous buffers and organic solvents. However, avoid the use of halogenated solvents and hexane.

Minichrom™ BioPro Columns can be cleaned, stored, and re-used in different applications.

Minichrom™ is a trademark of Repligen Corporation.

To purchase or learn more about screening columns, analytical columns, column accessories, or other YMC products, email a YMC representative at info@ymcamerica.com or call 888-341-8380.

About YMC America, Inc.
Established in 1980, YMC America, Inc. is worldwide full-service liquid chromatography company, which offers sales, technical product support, service, application assistance, purification services, contract synthesis and method development.

All YMC products are available worldwide through YMC's network of subsidiaries. This worldwide presence as a full-range chromatography supplier ensures that all YMC products are fully available and fully supported both locally and globally. See: https://www.ymcamerica.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Allentown, PA -- (SBWIRE) -- 06/03/2020 -- YMC products for preparative scale chromatography are described in detail in YMC's 28-page "Preparative Systems" brochure.

In addition to offering many types of separation media used in production scale preparative chromatography, YMC supplies several models and sizes of axial compression columns, fixed bed columns, slurry preparation products, and preparative scale pump and control systems, including explosion proof systems for use in hazardous environments.

Systems include conventional stainless steel designs, which are used for manufacturing scale purification of low MW organic compounds, pharmaceutical products, natural products, agricultural products, and food additives.

YMC also offers systems with non-metallic wetted parts for use with metal-sensitive biopharmaceutical products. Non-metallic systems are suitable for purification of biomolecules such as proteins, peptides, antibodies, and nucleic acids.

Included in the brochure are YMC glass columns for prep applications at lab scale or for pilot scale use.

Conventional stainless steel prep columns are featured with axial compression designs to simplify column packing. Axial compression is an easy way to displace the slurry solvent used during column packing and to promote uniform bed formation free of voids.

YMC offers axial compression columns in a number of sizes, from smaller semi-prep columns used in process development to large production scale systems.

Documentation and support for GMP compliance is also available at YMC.

Find the brochure on the YMC America website at: https://www.ymcamerica.com/wp-content/uploads/2018/09/Prep-Systems.pdf

Contact YMC America by email at info@ymcamerica.com or by phone at 888-341-8380.

About YMC America, Inc.
Established in 1980, YMC America, Inc. is worldwide full-service liquid chromatography company, which offers sales, technical product support, service, application assistance, purification services, contract synthesis and method development.

All YMC products are available worldwide through YMC's network of subsidiaries. This worldwide presence as a full-range chromatography supplier ensures that all YMC products are fully available and fully supported both locally and globally.

See: https://www.ymcamerica.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Allentown, PA -- (SBWIRE) -- 05/01/2020 -- For analysts interested in the quantitative separation of melatonin and other ingredients in over-the-counter (OTC) sleep aids, YMC has developed a fast and rugged gradient method offering excellent resolution between the compounds, and excellent peak shape and symmetry.

The gradient method uses HPLC water and acetonitrile as the mobile phase components, with no mobile phase buffering. The prototype 10-minute method includes column equilibration and is performed in standard HPLC mode on a 150 mm column packed with 3µm particles.

Melatonin elutes on the YMC-Triart C18 column under mobile phase conditions with 55% acetonitrile; the gradient ramp is used to accelerate the elution of other components under conditions with a higher concentration of organic solvent.

The gradient rate can be easily adjusted to accommodate the resolution requirements specific to the other analytes in the sample. Since the gradient contains no buffers, re-equilibration is straightforward. The ODS stationary phase – YMC-Triart C18 – remains stable and equilibrates quickly under the gradient ramp and step reset cycles.

The column used in the application is YMC-Triart C18, which is an ODS stationary phase based on a porous hybrid particle. Triart is mechanically, thermally, and chemically durable, so columns packed with Triart materials offer application versatility and long life.

It should be noted that the separation of melatonin is performed at 40°C, so the stability of the Triart C18 stationary phase will contribute to long column life. YMC-Triart C18 is also fully scalable for microLC, prep, UHPLC, and conventional HPLC.

For more information, visit https://www.ymcamerica.com/, call 888-341-8380, or email info@ymcamerica.com.

About YMC America, Inc.
Established in 1980, YMC America, Inc. is worldwide full-service liquid chromatography company, which offers sales, technical product support, service, application assistance, purification services, contract synthesis and method development.

All YMC products are available worldwide through YMC's network of subsidiaries. This worldwide presence as a full-range chromatography supplier ensures that all YMC products are fully available and fully supported both locally and globally.

See: https://www.ymcamerica.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm